|
Mutation Information
|
Mutation Site
|
I181X |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
Env |
Literature Information
|
PubMed PMID
|
33290394
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
PLoS pathogens |
|
Title
|
RV144 HIV-1 vaccination impacts post-infection antibody responses. |
|
Author
|
Mdluli T,Jian N,Slike B,Paquin-Proulx D,Donofrio G,Alrubayyi A,Gift S,Grande R,Bryson M,Lee A,Dussupt V,Mendez-Riveria L,Sanders-Buell E,Chenine AL,Tran U,Li Y,Brown E,Edlefsen PT,O'Connell R,Gilbert P,Nitayaphan S,Pitisuttihum P,Rerks-Ngarm S,Robb ML,Gramzinski R,Alter G,Tovanabutra S,Georgiev IS,Ackerman ME,Polonis VR,Vasan S,Michael NL,Kim JH,Eller MA,Krebs SJ,Rolland M |
|
Evidence
|
Because vaccine efficacy was strongest toward viruses with K169 or I181X, we expected that, in the vaccine group, neutralization would be stronger against viruses containing the K169 or I181X variants and lower against the vaccine-resistant variants, i.e.
|
|
|
HIV Mutation Detail Information